BioSpace News Archive

Pliant Therapeutics, Inc., a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, announced that the company will be presenting data at The Digital International Liver Congress™ 2020.

TeraRecon Inc., the leading provider of advanced visualization and artificial intelligence solutions, recently launched the Intuition Titanium subscription, a new offering that includes a robust set of enterprise AI capabilities with the inclusion of future AI enhancements.

Relay Therapeutics, Inc., a clinical-stage precision medicine company transforming the drug discovery process by leveraging unparalleled insights into protein motion, reported second quarter 2020 financial results.

Brain Scientific Inc., a medical device and technology company offering products and solutions related to the brain including neurology, AI, and machine learning, announced that its minimally invasive graphene electrode was selected as a finalist at the 2020 Epilepsy Foundation Shark Tank Competition.

A pre-scheduled independent Safety Monitoring Committee (SMC) has recommended that the U.S. Phase 2 COVID-19 study with opaganib continue with no changes; the study is more than 50% enrolled and enrollment is planned to be completed in the coming weeks

Pluristem Therapeutics Inc. announced that the U.S. Food and Drug Administration has cleared the Company’s Expanded Access Program for the use of its PLX-PAD cells to treat Acute Respiratory Distress Syndrome caused by COVID-19 outside of the Company’s ongoing Phase II COVID-19 study in the U.S.

Soligenix, Inc., a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced that its Senior Vice President and Chief Financial Officer, Jonathan Guarino, will deliver a corporate presentation at the LD Micro Conference, held virtually September 1-4, 2020.

The Phase 2 study aims to evaluate the dual antiviral and inflammation-controlling effects of the company’s LAU-7b oral drug candidate against COVID-19 infection

Leaps by Bayer and Northpond Ventures co-lead the investment to support development of next-generation immuno oncology treatments

Rocket Pharmaceuticals, Inc. announces that the U.S. FDA has granted Fast Track designation to RP-L401, the Company’s lentiviral vector -based gene therapy for the treatment of Infantile Malignant Osteopetrosis, a rare, severe monogenic bone resorption disorder characterized by skeletal deformities, neurologic abnormalities and bone marrow failure.